COMP <GO>
NVAX vs UNH // FORWARD P/E MULTIPLE
Novavax Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: NVAX 7
— UNH 6
▲ FORWARD P/E MULTIPLE LEADER: NVAX
LAST: $10.47 (+1.45%) • MKT CAP: $1.73B
forward-pe
3.5x
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
forward-pe
17.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVAX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVAX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 93.50% | 88.57% | +4.93 | NVAX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 11.47% | +73.53 | NVAX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 3.3x | 16.4x | -13.15 | NVAX | /valuation <GO> |
| Free Cash Flow Yield | -14.17% | 6.48% | -20.65 | UNH | /fcf-yield <GO> |
| Operating Margin | 40.30% | 4.82% | +35.48 | NVAX | /operating-margins <GO> |
| Net Profit Margin | 39.20% | 3.14% | +36.06 | NVAX | /net-margins <GO> |
| Revenue Growth (YoY) | 64.70% | 6.46% | +58.24 | NVAX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 3.12 | -2.92 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.9 | 59.2 | -14.32 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 3.5x | 17.1x | -13.59 | NVAX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.73B | $368.83B | -$367.10B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVAX REV | UNH REV | NVAX GROSS % | UNH GROSS % | NVAX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.12B | $447.57B | 93.5% | 88.7% | -$244.6M | $16.07B |
| FY 2024 | $682.2M | $400.28B | 70.3% | 88.3% | -$87.3M | $20.70B |
| FY 2023 | $983.7M | $371.62B | — | 89.6% | -$714.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVAX // BETA —
UNH // BETA 0.33